MAPS is pleased to share our 2023 Medical Metrics Benchmarking Report, based on findings from 51 leading organizations representing the Pharmaceutical, Biotech, and Medical and Diagnostic Device sectors.
As evidence generation becomes more advanced and integrated into Medical Affairs strategic plans, there is a greater need to maximize its impact by leveraging emerging digital technologies to communicate complex clinical and nonclinical data.
MAPS announces the election of Dr. Danie du Plessis as Chair of the MAPS Board of Directors. Du Plessis is currently Executive Vice-President (EVP) & Head of Medical Affairs at Kyowa Kirin International and is a senior pharmaceutical executive with 30 years’ experience.
This White Paper draws on the expertise of 10 senior Medical Affairs leaders across diverse global organizations to describe the role of Medical Affairs in ensuring the MedTech industry meets the challenges of high-quality evidence, objective measures, changes in the healthcare landscape, and more.
By using the framework of Explore, Educate, Embrace we can shape our approach to Health Equity by incorporating it into our daily work.
Streamlining the diagnostic odyssey requires educating medical professionals to recognize “rare encounters” and engage these patients with precision and compassion.
This article provides top-level framework and broad conceptual categories for understanding digital structures within Medical Affairs and biopharmaceutical/MedTech organizations, helping leaders to make organizational decisions to drive their digital strategy with intention and purpose.
This White Paper provides a foundational understanding of insights management, including the definition and value of insights, processes and technologies for insights management, and key challenges in implementation.
With a multibillion dollar investment from Microsoft and already 4 authorship credits on PubMed, ChatGPT is poised to disrupt Medical Affairs.
Based on discussions between 80 cross-industry Field Medical colleagues from small to large biopharmaceutical and medtech companies, this article highlights key actions for Medical Affairs teams to consider for implementation in their own organizations.